top of page
News & Updates
One of five biotech startups in MassBioDrive S23 cohort (Apr 2023)
MassBioDrive is run by MassBio, Massachusetts’ leading organization in life sciences, promoting industry growth, by representing 1,400+ members.
Through the eight week accelerator, we will get hands-on expert guidance, mentorship from biopharma leaders, and access to MA's largest biopharma network.
Through the eight week accelerator, we will get hands-on expert guidance, mentorship from biopharma leaders, and access to MA's largest biopharma network.
One of 11 ventures in 2023 Pagliuca Harvard Life Lab (Feb 2023)
Proud to be one of the 11 ventures to kick off the 2023 cohort of the Pagliuca Harvard Life Lab. The Pagliuca Harvard Life Lab is home to some of the most innovative minds working tirelessly to address some of the most pressing health challenges faced by our society. With cutting-edge resources and a collaborative environment, the Life Lab is the perfect breeding ground for breakthroughs that have the potential to change lives.
Presented at Biotech Showcase during JPM Conference (Jan 2023)
Our Cofounder and CEO, Luca Giani, presented Ilios Therapeutics' cutting-edge science and strategy on January 11, 2023 at the Biotech Showcase in San Francisco as part of the annual J.P. Morgan biotech conference alongside several other breakthrough technologies.
Ilios Accepted into the Boston Chapter of Nucleate (Dec 2022)
Nucleate facilitates the formation of pioneering life sciences companies, providing support for life science companies working on high-potential technologies.
Ilios joins the Pagliuca Harvard Life Lab (Dec 2022)
Ilios Therapeutics has officially joined the Pagliuca Harvard Life Lab operated by LabCentral. This state-of-the-art facility will provide us with the instruments, resources and support we need to advance our experimental plan and perform assays to test our proprietary new chemical entities against neurodegenerative diseases.
Ilios Joins MassChallenge 2022 Early-stage Startup Cohort (Jun 2022)
Ilios Tx joins more than 200 other ventures as part of this year's MassChallenge accelerator. Through the program Ilios gains access to MassChallenge's global network, world-class mentoring from industry experts, tailored programming, and unrivaled access to corporate partners.
Ilios' Co-Founder
Highlighted by NASDAQ (May 2023)
NASDAQ highlighted the work of Ilios Tx co-founder and CEO, Luca Giani, in creating innovative therapies against neurodegenerative diseases. The showcase is part of an initiative celebrating social entrepreneurs advancing the UN SDGs.
Ilios Welcomes Inaugural Internship Class (May 2023)
Ilios Tx is proud to announce its first internship class: Lourdes Amieva, Fernando Gómez, Laura Mena, and Maria Natera. The four biotech graduates will help Ilios advance its pathway to IND and continued drug discovery, both with traditional research and novel bioinformatic computational methods.
Finalist for Harvard President Innovation Challenge (Apr 2022)
The Presidential Innovation Challenge showcases some of Harvard's most promising student and alumni ventures. Selected teams have the opportunity to win a portion of non-dilutive funding, made possible by a gift from the Bertarelli Foundation.
Ilios Secures Funding from Allston Venture Fund (Apr 2022)
The Allston Venture Fund provides pre-seed, equity free investment for promising ventures led by Harvard students. The fund is backed by Bain Capital, General Catalyst, GETTYLAB, Highland Capital, Polaris Partners, and Underscore VC.
bottom of page